153 related articles for article (PubMed ID: 21040214)
1. Sorafenib efficacy in ovarian clear cell carcinoma revealed by transcriptome profiling.
Matsumura N; Mandai M; Okamoto T; Yamaguchi K; Yamamura S; Oura T; Baba T; Hamanishi J; Kang HS; Matsui S; Mori S; Murphy SK; Konishi I
Cancer Sci; 2010 Dec; 101(12):2658-63. PubMed ID: 21040214
[TBL] [Abstract][Full Text] [Related]
2. Identification of an ovarian clear cell carcinoma gene signature that reflects inherent disease biology and the carcinogenic processes.
Yamaguchi K; Mandai M; Oura T; Matsumura N; Hamanishi J; Baba T; Matsui S; Murphy SK; Konishi I
Oncogene; 2010 Mar; 29(12):1741-52. PubMed ID: 20062075
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models.
Chang YS; Adnane J; Trail PA; Levy J; Henderson A; Xue D; Bortolon E; Ichetovkin M; Chen C; McNabola A; Wilkie D; Carter CA; Taylor IC; Lynch M; Wilhelm S
Cancer Chemother Pharmacol; 2007 Apr; 59(5):561-74. PubMed ID: 17160391
[TBL] [Abstract][Full Text] [Related]
4. Two cases of recurrent ovarian clear cell carcinoma treated with sorafenib.
Koshiyama M; Matsumura N; Baba T; Yamaguchi K; Yoshioka Y; Konishi I
Cancer Biol Ther; 2014 Jan; 15(1):22-5. PubMed ID: 24096267
[TBL] [Abstract][Full Text] [Related]
5. Antitumor efficacy of recombinant human interleukin-2 combined with sorafenib against mouse renal cell carcinoma.
Iguchi M; Matsumoto M; Hojo K; Wada T; Matsuo Y; Arimura A; Abe K
Jpn J Clin Oncol; 2009 May; 39(5):303-9. PubMed ID: 19336449
[TBL] [Abstract][Full Text] [Related]
6. A synthetic retinoid, TAC-101 (4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid), plus cisplatin: potential new therapy for ovarian clear cell adenocarcinoma.
Ezawa S; Suzuki N; Ohie S; Higashiguchi A; Hosoi F; Kitazato K; Susumu N; Aoki D
Gynecol Oncol; 2008 Mar; 108(3):627-31. PubMed ID: 18048092
[TBL] [Abstract][Full Text] [Related]
7. Depletion of tumor-associated macrophages enhances the effect of sorafenib in metastatic liver cancer models by antimetastatic and antiangiogenic effects.
Zhang W; Zhu XD; Sun HC; Xiong YQ; Zhuang PY; Xu HX; Kong LQ; Wang L; Wu WZ; Tang ZY
Clin Cancer Res; 2010 Jul; 16(13):3420-30. PubMed ID: 20570927
[TBL] [Abstract][Full Text] [Related]
8. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.
Zorn KK; Bonome T; Gangi L; Chandramouli GV; Awtrey CS; Gardner GJ; Barrett JC; Boyd J; Birrer MJ
Clin Cancer Res; 2005 Sep; 11(18):6422-30. PubMed ID: 16166416
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature.
Adnane L; Trail PA; Taylor I; Wilhelm SM
Methods Enzymol; 2006; 407():597-612. PubMed ID: 16757355
[TBL] [Abstract][Full Text] [Related]
10. A novel retinoid, 4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid (TAC-101), induces apoptosis of human ovarian carcinoma cells and shows potential as a new antitumor agent for clear cell adenocarcinoma.
Suzuki N; Aoki D; Oie S; Horiuchi M; Hasegawa Y; Ezawa S; Suzuki A; Susumu N; Hosoi F; Kitazato K; Nozawa S
Gynecol Oncol; 2004 Sep; 94(3):643-9. PubMed ID: 15350353
[TBL] [Abstract][Full Text] [Related]
11. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
12. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
Pectasides D; Fountzilas G; Aravantinos G; Kalofonos C; Efstathiou H; Farmakis D; Skarlos D; Pavlidis N; Economopoulos T; Dimopoulos MA
Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
[TBL] [Abstract][Full Text] [Related]
13. Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma.
Procopio G; Verzoni E; Gevorgyan A; Mancin M; Pusceddu S; Catena L; Platania M; Guadalupi V; Martinetti A; Bajetta E
Oncology; 2007; 73(3-4):204-9. PubMed ID: 18418013
[TBL] [Abstract][Full Text] [Related]
14. Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors.
Dal Lago L; D'Hondt V; Awada A
Oncologist; 2008 Aug; 13(8):845-58. PubMed ID: 18695262
[TBL] [Abstract][Full Text] [Related]
15. c-MET as a Potential Therapeutic Target in Ovarian Clear Cell Carcinoma.
Kim HJ; Yoon A; Ryu JY; Cho YJ; Choi JJ; Song SY; Bang H; Lee JS; Cho WC; Choi CH; Lee JW; Kim BG; Bae DS
Sci Rep; 2016 Dec; 6():38502. PubMed ID: 27917934
[TBL] [Abstract][Full Text] [Related]
16. Treatment issues in clear cell carcinoma of the ovary: a different entity?
Pectasides D; Pectasides E; Psyrri A; Economopoulos T
Oncologist; 2006; 11(10):1089-94. PubMed ID: 17110628
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.
Escudier B; Eisen T; Stadler WM; Szczylik C; Oudard S; Staehler M; Negrier S; Chevreau C; Desai AA; Rolland F; Demkow T; Hutson TE; Gore M; Anderson S; Hofilena G; Shan M; Pena C; Lathia C; Bukowski RM
J Clin Oncol; 2009 Jul; 27(20):3312-8. PubMed ID: 19451442
[TBL] [Abstract][Full Text] [Related]
18. Targeting STAT3 by HO3867 induces apoptosis in ovarian clear cell carcinoma.
Bixel K; Saini U; Kumar Bid H; Fowler J; Riley M; Wanner R; Deepa Priya Dorayappan K; Rajendran S; Konishi I; Matsumura N; Cohn DE; Selvendiran K
Int J Cancer; 2017 Nov; 141(9):1856-1866. PubMed ID: 28646535
[TBL] [Abstract][Full Text] [Related]
19. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer.
Blumenschein GR; Gatzemeier U; Fossella F; Stewart DJ; Cupit L; Cihon F; O'Leary J; Reck M
J Clin Oncol; 2009 Sep; 27(26):4274-80. PubMed ID: 19652055
[TBL] [Abstract][Full Text] [Related]
20. Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation.
Plastaras JP; Kim SH; Liu YY; Dicker DT; Dorsey JF; McDonough J; Cerniglia G; Rajendran RR; Gupta A; Rustgi AK; Diehl JA; Smith CD; Flaherty KT; El-Deiry WS
Cancer Res; 2007 Oct; 67(19):9443-54. PubMed ID: 17909054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
